Medicine Use in Children Aged Under 12 Years: Population Survey in Finland
Abstract
Purpose
To study the prevalence of prescribed and over-the-counter (OTC) medicine use in children under 12 years of age in Finland and to examine factors associated with the medicine use.
Methods
A nationwide population survey was carried out in Finland in spring 2018 with a random sample of children under 12 years (n = 8000). A response rate of 24% (n = 1921) was attained. The questionnaire was sent to the child's primary guardian. Current use of prescribed medicines and the use of OTC medicines in the preceding 2 days were the main outcome measures.
Results
Of all the children 19% had used prescribed medicines, 15% OTC medicines, and 31% either prescription or OTC medicines during the preceding 22 days. Children's health related factors were positively associated with prescribed medicine use including fairly good to poor health status, symptoms experienced, and illnesses diagnosed by a physician. The guardian's healthcare education and use of prescribed medicines were also associated with children's prescribed medicine use. Symptoms of illnesses and fairly good health status were found to be associated with childrens' use of OTC medicines.
Conclusions
The use of medicines in children under 12 years of age is quite common in Finland. As expected, children's health-related factors were associated with medicine use. Also, guardians' healthcare education and the use of prescribed medicines were associated with children's prescription medicine use. Children's medicine use should be continuously monitored and investigated further to identify the reasons leading to appropriate and inappropriate medicine use in children.
Full text (onlinelibrary.wiley.com)
Authors
Joonas Kesti, Leena Saastamoinen, Piia Lavikainen, Kati Sepponen
Additional Information
- Peer-Reviewed: yes.
- Open Access: yes.
- Cite as: Kesti, J., Saastamoinen, L., Lavikainen, P., & Sepponen, K. (2022). Medicine use in children aged under 12 years: Population survey in Finland. Pharmacoepidemiology and drug safety, 32(2), 266–276. https://doi.org/10.1002/pds.5539